ABBV
Price
$210.50
Change
+$2.57 (+1.24%)
Updated
Aug 29, 04:59 PM (EDT)
Capitalization
371.68B
56 days until earnings call
NVS
Price
$126.51
Change
+$0.04 (+0.03%)
Updated
Aug 29, 04:59 PM (EDT)
Capitalization
244.29B
60 days until earnings call
Interact to see
Advertisement

ABBV vs NVS

Header iconABBV vs NVS Comparison
Open Charts ABBV vs NVSBanner chart's image
ABBVIE
Price$210.50
Change+$2.57 (+1.24%)
Volume$29.73K
Capitalization371.68B
Novartis AG
Price$126.51
Change+$0.04 (+0.03%)
Volume$13.14K
Capitalization244.29B
ABBV vs NVS Comparison Chart in %
Loading...
ABBV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ABBV vs. NVS commentary
Aug 30, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABBV is a StrongBuy and NVS is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 30, 2025
Stock price -- (ABBV: $207.92 vs. NVS: $126.47)
Brand notoriety: ABBV: Notable vs. NVS: Not notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: ABBV: 82% vs. NVS: 42%
Market capitalization -- ABBV: $371.68B vs. NVS: $244.29B
ABBV [@Pharmaceuticals: Major] is valued at $371.68B. NVS’s [@Pharmaceuticals: Major] market capitalization is $244.29B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $656.73B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $88.99B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABBV’s FA Score shows that 2 FA rating(s) are green whileNVS’s FA Score has 2 green FA rating(s).

  • ABBV’s FA Score: 2 green, 3 red.
  • NVS’s FA Score: 2 green, 3 red.
According to our system of comparison, NVS is a better buy in the long-term than ABBV.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABBV’s TA Score shows that 4 TA indicator(s) are bullish while NVS’s TA Score has 5 bullish TA indicator(s).

  • ABBV’s TA Score: 4 bullish, 4 bearish.
  • NVS’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, ABBV is a better buy in the short-term than NVS.

Price Growth

ABBV (@Pharmaceuticals: Major) experienced а -0.75% price change this week, while NVS (@Pharmaceuticals: Major) price change was -0.28% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -1.84%. For the same industry, the average monthly price growth was +1.29%, and the average quarterly price growth was +11.90%.

Reported Earning Dates

ABBV is expected to report earnings on Oct 24, 2025.

NVS is expected to report earnings on Oct 28, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (-1.84% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ABBV($372B) has a higher market cap than NVS($244B). ABBV has higher P/E ratio than NVS: ABBV (100.19) vs NVS (18.45). NVS YTD gains are higher at: 34.645 vs. ABBV (20.231). NVS has higher annual earnings (EBITDA): 22.7B vs. ABBV (14.2B). NVS has more cash in the bank: 7B vs. ABBV (6.47B). NVS has less debt than ABBV: NVS (32.6B) vs ABBV (70.5B). ABBV has higher revenues than NVS: ABBV (58.3B) vs NVS (55.2B).
ABBVNVSABBV / NVS
Capitalization372B244B152%
EBITDA14.2B22.7B63%
Gain YTD20.23134.64558%
P/E Ratio100.1918.45543%
Revenue58.3B55.2B106%
Total Cash6.47B7B92%
Total Debt70.5B32.6B216%
FUNDAMENTALS RATINGS
ABBV vs NVS: Fundamental Ratings
ABBV
NVS
OUTLOOK RATING
1..100
1825
VALUATION
overvalued / fair valued / undervalued
1..100
89
Overvalued
14
Undervalued
PROFIT vs RISK RATING
1..100
1113
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
2446
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
65n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NVS's Valuation (14) in the Pharmaceuticals Major industry is significantly better than the same rating for ABBV (89). This means that NVS’s stock grew significantly faster than ABBV’s over the last 12 months.

ABBV's Profit vs Risk Rating (11) in the Pharmaceuticals Major industry is in the same range as NVS (13). This means that ABBV’s stock grew similarly to NVS’s over the last 12 months.

ABBV's SMR Rating (100) in the Pharmaceuticals Major industry is in the same range as NVS (100). This means that ABBV’s stock grew similarly to NVS’s over the last 12 months.

ABBV's Price Growth Rating (24) in the Pharmaceuticals Major industry is in the same range as NVS (46). This means that ABBV’s stock grew similarly to NVS’s over the last 12 months.

ABBV's P/E Growth Rating (100) in the Pharmaceuticals Major industry is in the same range as NVS (100). This means that ABBV’s stock grew similarly to NVS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ABBVNVS
RSI
ODDS (%)
Bearish Trend 2 days ago
42%
Bearish Trend 2 days ago
52%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
48%
Bearish Trend 2 days ago
40%
Momentum
ODDS (%)
Bullish Trend 2 days ago
67%
Bullish Trend 2 days ago
55%
MACD
ODDS (%)
Bullish Trend 2 days ago
67%
Bullish Trend 2 days ago
55%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
45%
Bearish Trend 2 days ago
44%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
61%
Bullish Trend 2 days ago
46%
Advances
ODDS (%)
Bullish Trend 8 days ago
57%
Bullish Trend 3 days ago
49%
Declines
ODDS (%)
Bearish Trend 2 days ago
44%
Bearish Trend 24 days ago
45%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
38%
Bearish Trend 2 days ago
39%
Aroon
ODDS (%)
Bullish Trend 2 days ago
61%
Bearish Trend 2 days ago
31%
View a ticker or compare two or three
Interact to see
Advertisement
ABBV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
ROAM27.140.21
+0.77%
Hartford Multifactor Emerging Mkts ETF
GWX39.360.27
+0.69%
SPDR® S&P® International Small Cap ETF
DBAW38.390.06
+0.16%
Xtrackers MSCI All World exUS Hdg Eq ETF
USMV94.03-0.03
-0.03%
iShares MSCI USA Min Vol Factor ETF
REKT18.11-0.07
-0.37%
Direxion Daily Crypto Industry Bear1XETF

NVS and

Correlation & Price change

A.I.dvisor indicates that over the last year, NVS has been closely correlated with GSK. These tickers have moved in lockstep 68% of the time. This A.I.-generated data suggests there is a high statistical probability that if NVS jumps, then GSK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NVS
1D Price
Change %
NVS100%
-0.33%
GSK - NVS
68%
Closely correlated
-1.18%
AZN - NVS
61%
Loosely correlated
+0.08%
PFE - NVS
57%
Loosely correlated
-1.87%
JNJ - NVS
54%
Loosely correlated
-0.76%
SNY - NVS
54%
Loosely correlated
-0.34%
More